China’s Beijing InnoCare Pharma (HKG: 9969) announced that an investigational new drug (IND) filing for its in-house developed BCL2 inhibitor ICP-248 has been accepted for review by the National Medical Products Administration (NMPA). ICP-248 is a Category 1 innovative drug with independently held intellectual property rights.
Drug Profile
InnoCare plans to develop the molecule to treat malignant hematological tumors such as non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). ICP-248 can specifically bind to BCL2, relieve the inhibition of the mitochondrial apoptosis pathway caused by BCL2 overexpression, release and activate pro-apoptotic proteins, increase the permeability of the mitochondrial membrane, and release cytochrome c. The drug can also activate Caspase-mediated apoptosis cascade, restore and promote tumor cell apoptosis, and exert anti-tumor effects.-Fineline Info & Tech
